Y. Chen

发表

A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2).

J. Shih, V. Miller, Yuh-Min Chen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.

R. Robles, J. Infante, M. Tortorici, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

N. Reinmuth, Y. Shrestha, Haiyi Jiang, 2019, Annals of Oncology.

1331PDetection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms

S. Patel, Y. Wu, C. Zhou, 2017 .

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

N. Reinmuth, N. Shire, Haiyi Jiang, 2019, Journal of Thoracic Oncology.

LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2

Minhu Chen, Zhengming Chen, G. Shao, 2020 .

Abstract P3-14-02: Phase 1 Dose-Escalation Study of the Heat Shock Protein 90 Inhibitor BIIB021 with Trastuzumab in HER2+ Metastatic Breast Cancer

P. Munster, S. Moulder, S. Modi, 2010 .

888PPRECLINICAL AND EARLY CLINICAL ACTIVITY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) EXPORTIN 1 (XPO1) ANTAGONIST SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER (OVCA).

P. Dottino, J. Martignetti, A. Razak, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC).

G. Abou-Alfa, T. Meyer, R. Miksad, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

Y. Jiang, Y. Ba, R. Xu, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

1263PAFATINIB (A) FOLLOWED BY A + PACLITAXEL (P) OR INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC) IN PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG: SUBGROUP ANALYSIS OF LUX-LUNG 5 (LL5).

J. Strausz, F. de Marinis, D. Planchard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1265PPATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING AFATINIB (A) MONOTHERAPY FOLLOWED BY A + PACLITAXEL (A + P) VS INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC): LUX-LUNG 5 (LL5).

F. de Marinis, D. Planchard, M. Schuler, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)

S. Patel, M. Othus, L. Korde, 2022, Annals of Oncology.

Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

G. Abou-Alfa, A. El-Khoueiry, T. Meyer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

532MO A phase Ib study of TQB2450 in combination with anlotinib in patients with advanced solid tumour

Y. Xin, Ying Cheng, Changping Wu, 2020 .

LBA18 Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

H. Denys, S. Tolaney, J. Nadal, 2022, Annals of Oncology.

AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS).

M. Ahn, Y. Wu, C. Zhou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

B. Han, K. Nan, F. Jin, 2018, Journal of Thoracic Oncology.

OA03.03 Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer

P. Bunn, A. Navarro, A. Dowlati, 2019, Journal of Thoracic Oncology.

RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 dose-defining phase.

P. Bunn, A. Navarro, L. Paz-Ares, 2019, Journal of Clinical Oncology.

Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

G. Abou-Alfa, A. El-Khoueiry, R. Miksad, 2019, Annals of Oncology.

A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON‐HODGKIN'S LYMPHOMA

Craig B. Davis, R. Houot, S. Patel, 2017 .

P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN

N. Reinmuth, Haiyi Jiang, N. Byrne, 2021 .

A SINGLE‐ARM, OPEN‐LABEL, PILOT TRIAL OF AUTOLOGOUS CD7‐CAR‐T CELLS FOR CD7 POSITIVE RELAPSED AND REFRACTORY T‐LYMPHOBLASTIC LEUKEMIA/LYMPHOMA

X. Wang, Zhaoming Li, G. Pan, 2021, Hematological Oncology.

120P Neoadjuvant immunochemotherapy of pembrolizumab plus chemotherapy in resectable non-small cell lung cancer

Y. Chen, B. Yan, J. You, 2023, Journal of Thoracic Oncology.

1354POsimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: Updated Phase II study results including progression-free survival (PFS)

M. Ahn, Y. Wu, C. Zhou, 2017 .

P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC

X. Jiang, J. Fang, F. Wu, 2021 .

OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

X. Jiang, J. Fang, C. Zhu, 2019, Journal of Thoracic Oncology.

Phase II randomized trial of erlotinib versus vinorelbine in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) aged ≥70 years in Taiwan.

J. Whang‐Peng, R. Perng, C. Tsai, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.